Lexaria的研究显示,其交付技术与主要药物影响与潜在身体组成和血压效益相匹配。 Lexaria's study shows its delivery tech matches key drug effects with potential body composition and blood pressure benefits.

Lexaria生物科学在澳大利亚公布了其第一阶段b研究的最后结果,显示其脱水TECHTM交付平台产生了与Rybelsusá相似的代谢结果,用于含硫酸盐、tirzepatide和《生物多样性公约》配方。 Lexaria Bioscience has released final results from its Phase 1b study in Australia, showing its DehydraTECH™ delivery platform produced comparable metabolic outcomes to Rybelsus® for semaglutide, tirzepatide, and CBD formulations. DHT-司美格鲁肽显示脂肪减少适度，瘦体重减少幅度较小，暗示其体成分可能更佳。 DHT-semaglutide showed modest fat loss with minimal lean mass reduction, suggesting a potentially better body composition profile. DHT-CBD导致非高血压参与者持续减少血压,支持高血压患者的发展。 DHT-CBD led to sustained blood pressure reductions in non-hypertensive participants, supporting its development for hypertension. CBD水平在第16周内仍可检测，但由于检测问题，司美格鲁肽水平无法检测，尽管ELISA检测确认了存在。 CBD levels remained detectable through week 16, but semaglutide levels were undetectable due to assay issues, though ELISA testing confirmed presence. 没有关于重大生活质量问题的报告。 No major quality of life concerns were reported. 成果正在指导Lexaria的2026年发展计划。 Results are guiding Lexaria’s 2026 development plans.